.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average consequence of 11 months, patients along with metastatic intestinal lumps that got biomarker-matched therapies based upon circulating cyst DNA profiling revealed a higher scientific benefit than those obtaining unmatched treatment.